The angiotensin II type 1 receptor antagonist (angio-tensin receptor blocker [ARB]) losartan has been shown in the LIFE (Losartan Intervention for Endpoint Reduction in Hypertension) study to ...

Forty-eight of the patients completed the study. The four treatment groups were of similar age but less balanced with respect to gender (placebo, 6/8 [female/male]; 25 mg losartan, 6/5; 100 mg ...

This is a multicenter randomized controlled trial comparing losartan vs placebo for outpatients with COVID. Every patient that is tested in the ED and drive through clinic will receive a brochure with ...

The combination product is not recommended for patients with hepatic impairment because losartan is usually initiated in this group of patients at a dosage of 25 mg once daily. The combination ...